M
Matthew Hatton
Researcher at Weston Park Hospital
Publications - 101
Citations - 4221
Matthew Hatton is an academic researcher from Weston Park Hospital. The author has contributed to research in topics: Lung cancer & Medicine. The author has an hindex of 23, co-authored 84 publications receiving 3386 citations. Previous affiliations of Matthew Hatton include Doncaster Royal Infirmary & National Health Service.
Papers
More filters
Journal ArticleDOI
Prophylactic Cranial Irradiation in Extensive Small-Cell Lung Cancer
Berend J. Slotman,Corinne Faivre-Finn,G.W.P.M. Kramer,E.M. Rankin,Michael Snee,Matthew Hatton,Pieter E. Postmus,Laurence Collette,Elena Musat,Suresh Senan +9 more
TL;DR: Prophylactic cranial irradiation reduces the incidence of symptomatic brain metastases and prolongs disease-free and overall survival and did not have a clinically significant effect on global health status.
Journal ArticleDOI
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: The TNT Trial
Andrew Tutt,Andrew Tutt,Holly Tovey,Maggie C.U. Cheang,Sarah Kernaghan,Lucy Kilburn,Patrycja Gazinska,Julie Owen,Jacinta Abraham,Sophie Barrett,Peter Barrett-Lee,Robert S. Brown,Robert S. Brown,Stephen Chan,Mitchell Dowsett,Mitchell Dowsett,James M. Flanagan,Lisa Fox,Anita Grigoriadis,Alexander Gutin,Catherine Harper-Wynne,Matthew Hatton,Katherine A. Hoadley,Jyoti Parikh,Peter J. Parker,Peter J. Parker,Charles M. Perou,Rebecca Roylance,Vandna Shah,Adam Shaw,Ian E. Smith,Kirsten Timms,Andrew M Wardley,Gregory C. Wilson,Cheryl Gillett,Jerry S. Lanchbury,Alan Ashworth,Nazneen Rahman,Nazneen Rahman,Mark Harries,Paul Ellis,Sarah E Pinder,Judith M Bliss +42 more
TL;DR: The phase 3 TNT Trial in subjects with triple-negative breast cancer supports the superiority of carboplatin over docetaxel in BRCA1/2-mutated tumors and a greater response to taxanes in the nonbasal subtype, and concludes that patients with advanced TNBC benefit from characterization of BRC a/2 mutations, but not BRC1 methylation or Myriad HRD analyses, to inform choices on platinum-based chemotherapy.
Journal ArticleDOI
Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial
Ben J. Slotman,Harm van Tinteren,J. Praag,J. Knegjens,Sherif Y. El Sharouni,Matthew Hatton,Astrid Keijser,Corinne Faivre-Finn,Suresh Senan +8 more
TL;DR: Thoracic radiotherapy in addition to prophylactic cranial irradiation should be considered for all patients with extensive stage small-cell lung cancer who respond to chemotherapy.
Journal ArticleDOI
Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of systematic review.
David Gilligan,Marianne Nicolson,Ian E. Smith,Harry J.M. Groen,Otilia Dalesio,Peter Goldstraw,Matthew Hatton,Penelope Hopwood,Christian Manegold,Franz M.N.H. Schramel,Hans Smit,Jan P. van Meerbeeck,Matthew Nankivell,Mahesh K. B. Parmar,C. Pugh,Richard Stephens +15 more
TL;DR: There was no evidence of a difference in overall survival with neo-adjuvant chemotherapy, but the result is statistically consistent with previous trials, and therefore adds considerable weight to the current evidence.
Journal ArticleDOI
Prophylactic Cranial Irradiation in Extensive Disease Small-Cell Lung Cancer: Short-Term Health-Related Quality of Life and Patient Reported Symptoms--Results of an International Phase III Randomized Controlled Trial by the EORTC Radiation Oncology and Lung Cancer Groups
Berend J. Slotman,Murielle Mauer,Andrew Bottomley,Corinne Faivre-Finn,G.W.P.M. Kramer,E.M. Rankin,Michael Snee,Matthew Hatton,Pieter E. Postmus,Laurence Collette,Suresh Senan +10 more
TL;DR: Prophylactic cranial irradiation in patients with extensive-disease small-cell lung cancer (ED-SCLC) leads to significantly fewer symptomatic brain metastases and improved survival and PCI should be offered to all responding ED SCLC patients.